Nycomed US makes executive appointments from King
This article was originally published in Scrip
Nycomed US has appointed three new executives, all of whom were previously employees at King Pharmaceuticals (acquired by Pfizer in February 2011). Brian Markison, formerly chairman and CEO of King, joins as CEO; Jeff Bailey, previously King-Pfizer Pharmaceuticals' chief commercial officer, will serve as COO; and John Golubieski, King-Pfizer's former senior vice-president of financial planning & analysis, joins as CFO. Mr Markison currently serves on the boards of Immunomedics, Rosetta Genomics and the Komen Foundation for South/Central New Jersey.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.